Accuray Incorporated (ARAY)

Market Cap	216.19M
Revenue (ttm)	447.48M
Net Income (ttm)	-14.55M
Shares Out	99.17M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	22.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	336,583
Open	2.180
Previous Close	2.200
Day's Range	2.140 - 2.210
52-Week Range	2.100 - 4.300
Beta	1.47
Analysts	Strong Buy
Price Target	8.25 (+278.44%)
Earnings Date	May 1, 2024

About ARAY

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 8, 2007
• Employees: 1,024
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAY

Financial Performance

In 2023, Accuray's revenue was $447.61 million, an increase of 4.12% compared to the previous year's $429.91 million. Losses were -$9.28 million, 73.6% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ARAY stock is "Strong Buy." The 12-month stock price forecast is $8.25, which is an increase of 278.44% from the latest price.

Price Target

$8.25

(278.44% upside)

Analyst Consensus: Strong Buy